The partners will study the use of a test for Ly6E(hi) neutrophils as a biomarker for treatment response in five cancer indications.

In the Phase II LUMINOSITY study, Emrelis (telisotuzumab vedotin-tllv), a first-in-class c-Met-directed antibody-drug ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. Immutep climbed 16% to $2.11 on ...

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

The FDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), the first targeted therapy for previously ...

AbbVie ABBV announced that the FDA has granted accelerated approval to its antibody-drug conjugate (ADC), telisotuzumab ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

The test detects the MET protein that is over-expressed in some patients with non-squamous non-small cell lung cancer.